Healthcare
Tuesday, April 26, 2016
BRIEF-Quantum genomics receives authorisation to begin Phase IIA multicentric European trial
* Regulatory authorisations received in France to begin Phase IIA multicentric European
trial for heart failure
Source text for Eikon:
Further company coverage:
(Gdynia Newsroom)
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment